The purpose of the KONFIDENT Study is to understand the effects of an investigational oral medication called KVD900 in adolescents and adults (12 years of age and older) with HAE type I or type II. Doctors are studying 2 different doses to see which one may be best as a safe on-demand treatment for HAE attacks.

You may be able to participate if:

The KONFIDENT Study lasts approximately 25 weeks with 6 visits or televisits (phone call or video chat) for health checks and tests at no cost to you.

If you join this study, you will treat 3 HAE attacks, with either 300mg or 600mg of KVD900 or placebo, in a random order. The placebo looks like KVD900 but does not have medicine in it. This helps the researchers to better understand the effects of KVD900.

You will use an electronic diary to answer questions about your HAE attacks and to determine if you should treat the attack using the study medication or your regular on-demand medication.

The study medication comes as tablets to be taken by mouth. You will receive enough study medication to treat 3 separate, eligible HAE attacks. Take the study medication provided to you as soon as possible after the start of the attack.

Each time you take the study medication, you will have a televisit (phone call or video chat) with your study doctor or study staff to see how you are feeling and to go over the information in your diary.
You will be monitored continuously throughout the study for any changes in health or potential side effects.